The ALLHAT-LLT study;L'étude clinique du mois l'étude ALLHAT-LLT

Revue Medicale de Liege

Volumn 58, Issue 1, 2003, Pages 53-58

  Kulbertus, H ^a   Scheen, A J ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Cholesterol Statins; Coronary heart disease; Hypertension; Pravastatin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

AGE DISTRIBUTION; DRUG EFFICACY; FOLLOW UP; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MORALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RACE DIFFERENCE; REVIEW; RISK FACTOR; SAMPLING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 18744427054     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Scheen AJ, Krzesinski JM.- L'étude clinique du mois. Quel antihypertenseur en première intention? Résultats de l'étude ALLHAT. Rev Med Liege, 2003, 58, 47-52.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.- Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288, 2981-2997.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.- Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA, 2002, 288, 2998-3007.
4. Scandinavian Simvastatin Survival Study Group.-Randomised trial of cholesterol lowering in 4444 patients with coronary heart disesase: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-1389.
5. Summary of the second report of the National Cholesterol Education Program (NCEP).- Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel II). JAMA, 1993, 269, 3015-3023.
6. Heart Protection Study Collaborative Group.-MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals. Lancet, 2002, 360, 7-22.
7. Kulbertus H, Scheen AJ.- L'étude clinique du mois. La MRC/BHF Heart Protection Study. Rev Med Liège, 2002, 57, 613-616.
8. Scheen AJ.- La non-observance thérapeutique: problème majeur pour la prévention des maladies cardiovasculaires. Rev Med Liège, 1999, 54, 914-920.
9. Shepherd J, Cobbe SM, Ford J et al. for the West of Scotland Coronary Prevention Study Group.- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med., 1995,333, 1301-1307.
10. Sacks FM, Pfeffer MA, Moye IA et al for The Cholesterol and Recurrent Events Trial Investigators.- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996, 335, 1001-1009.
11. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group.- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998, 339, 1349-1357.
12. Pasternak RC.- Editorial: "The ALLHAT Lipid Lowering Trial - Less is less". JAMA, 2002, 288, 3042-3044.
13. Downs JR, Clearfield M, Weis S et al for the AFCAPS/TexCAPS Research Group.- Primary prevention of coronary acute events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA, 1998, 279, 1615-1622.
14. Post Coronary Bypass Graft Trial Investigators.- The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary artery by-pass grafts. N Engl J Med, 1997, 336, 153-152.
15. Serruys PW, de Feyter P, Macaya C et al.- Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA, 2002, 287, 3215-3222.
16. Corsini A, Bellosta S, Baetta R et al.- New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther, 1999, 84, 413-428. (cité dans 3).
17. Shepherd J, Blauw GJ, Murphy MB, et al. On behalf of the PROSPER study group.- Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002, 360, 1623-1630.
18. Kulbertus H, Scheen AJ.- L'étude clinique du mois. L'étude PROSPER (PROspective Study of Pravastatin in the Elderly at Risk). Rev Med Liège, 2002, 57, 809-813.
19. Scheen AJ.- Le risque cardio-vasculaire lié à l'hyper-cholestérolémie: d'un continuum à la notion de normalité, de seuil d'intervention et d'objectif thérapeutique. Rev Med Liège, 1999, 54, 17-21.
20. Gordon DJ, Proschan MA, Rossouw JE.- Cholesterol lowering and cardiovascular disease (cité dans réf. 3). 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke, Florence, June 12-15, 2002. Abstract and slides available at:htth://www.lorenzinifoundation.org/gr2002/slides/(search by author: Rossouw JE).
21. Scheen AJ.- Evidence-based medicine. Apport des essais cliniques contrôlés. Rev Med Liège, 2000, 55, 216-219.
22. Phillips LS, Branch WT Jr, Cook CB, et al.- Clinical inertia. Ann Intern Med, 2001, 135, 824-834 (cité dans 13).